The company's primary aim is to reduce suffering and death from lung disease. Currently company executives are unpaid with all monies employed to finance our research and development programme. Nevertheless, there is a well-documented, continuously-growing, global requirement for respiratory aids. We expect to move to production in three to four years. At that time, we anticipate a large and expanding market for the Haemair lung. Providing that the development programme continues successfully, we predict that the Company will be financially and operationally successful in an international arena.

The Company's finance comes from two sources, private equity – fully paid up – and grants from the Welsh Assembly Government. In addition to placement of shares with private investors, the University of Wales at Swansea (where the initial R & D programme is being run) has been granted share options executable over a two-year period.

If you are interested in becoming a shareholder in Haemair, please contact Professor W R Johns ( ), Managing Director of Haemair Ltd. Alternatively, information can be obtained by post or telephone (see the Contact Us page on this website). Subject to appropriate regulatory requirements in connection with financial promotions, we can send you our Business Plan. We are currently issuing a share tranche that we expect to close in May 2008. Following this tranche, we do not anticipate further tranches until late 2009 or early 2010, by which time we expect to have made significant technical advances. Our technical and business programme has been assessed as suitable for Government support. Additionally, Haemair Ltd is registered under the UK Enterprise Investment Scheme (EIS) and under the Corporate Venturing Scheme. Thus, shares in Haemair attract UK Tax relief both on the share purchase and on capital gains. Haemair shares are also exempt from UK Inheritance Tax. If you are unfamiliar with EIS you may wish to check the Revenue and Customs web site, or to seek professional advice.

INVESTMENT WARNING: Investment in private companies such as Haemair carries high risks as well as the possibility of high rewards. It is consequently very speculative and you should be aware that no established market exists for the trading of shares in private companies, and such shares are not easily realisable. It must be appreciated that there could be difficulty in selling such investments at a reasonable price and, in some circumstances, it may be difficult to sell them at any price. Accordingly you should consider very carefully whether such investments are suitable in the light of your circumstances and commitments and the financial resources available to you. Engaging in any investment activity may expose you to a significant risk of losing all of your investment and before investing in Haemair, you are strongly advised to take advice from a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on investments of this nature.